NCT06616415View on ClinicalTrials.gov

A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

May 13, 2026

Study Completion Date

May 13, 2026

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Belumosudil

Pharmaceutical form: Tablet Route of administration: Oral

Trial Locations (2)

100045

Investigational Site Number : 1560001, Beijing

200127

Investigational Site Number : 1560002, Shanghai

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06616415 - A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies | Biotech Hunter | Biotech Hunter